Safety Study of ASONEP (Sonepcizumab/LT1009) to Treat Advanced Solid Tumors

NCT00661414 | Completed Phase 1

• 1 other identifier: LT1009-Onc-001
• Study Type: interventional
• Target: 37
• Locations: 1 country
• Sites: 3

Brief Summary

The purpose of this study is to determine the safety, tolerability and highest dose of ASONEP that can safely be administered to patients with cancer who are no longer being helped by standard treatments.

Conditions

Solid Tumors

Keywords

Cancer; Solid tumors

Outcome Measures

Primary Outcomes (1)

• Safety

  Jan 2009

Interventions

ASONEP (sonepcizumab/LT1009) BIOLOGICAL

ASONEP \[sonepcizumab/LT1009\] is supplied as a colorless,particulate-free, pH 6.5, sterile solution containing approximately 10 mg/mL or 20 mg/mL of drug. The candidate drug is intended for single intravenous (iv) use administered over 90 minutes on a weekly basis.

Eligibility Criteria

• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

• Subjects must be 18 years old.
• Must have a confirmed diagnosis of solid tumor that has been refractory to prior therapy and for which no additional therapy of known benefit is available.
• Must have measurable or non-measurable disease as defined by RECIST guidelines.
• Be male or non-pregnant, non-lactating female. A negative pregnancy test within one week prior to the start of the study if a female of childbearing potential.
• Subjects and their partners with reproductive potential must agree to use an effective contraceptive method (as deemed by the Investigator) while the subject is on study treatment and for 30 days after the last treatment.
• Must have a life expectancy of at least 3 months.
• Must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2
• Must not be receiving any concurrent anticancer therapy.
• At least 4 weeks must have elapsed between any prior systemic treatment for the cancer (6 weeks for mitomycin and nitrosourea) and first dose of treatment on this protocol; at least 4 weeks must have elapsed between any prior radiation treatment for the cancer or major surgical procedure and the first dose of treatment on this protocol; all acute and chronic toxicities from prior treatment must have recovered to ≤ grade 1. Subjects with prostate cancer on Lupron® will be allowed to continue their treatment.
• Must have physical integrity of the gastrointestinal tract.
• Must have adequate organ and immune function as indicated by the following laboratory values:
• Serum creatinine \<1.5 x ULN or
• Estimated creatinine clearance \>45mL/min,
• Total Bilirubin \<2.0mg/dL (\<34.2umol/L),
• AST (SGOT) \& ALT (SGPT) \<3 x ULN,

You may not qualify if:

• Clinical evidence of active CNS involvement by malignancy. Subjects whose brain metastases were treated with radiation more than 8 weeks prior to entry on the trial, off steroids for at least 4 weeks, and with no evidence of disease progression in the brain for a minimum of 8 weeks are eligible for the trial.
• Active and uncontrolled infection.
• Hematologic cancers.
• Any uncontrolled medical problems, unrelated to the malignancy, or of sufficient severity that in the opinion of the Investigator, impair a subject's ability to give informed consent or unacceptably reduce the safety of the proposed treatment.
• Neurological or psychiatric disorders that would interfere with consent or study follow-up.
• Known or suspected intolerance or hypersensitivity to the study materials or closely related compounds\] or any of their stated ingredients.
• History of alcohol or other substance abuse within the last year.
• Concurrent use of steroids or other immune suppressive agent.
• Known positive test for HIV.
• Evidence of bowel obstruction because of the theoretical possibility of GI perforation with an anti-angiogenesis agent.
• Female subjects who are pregnant or lactating.
• Subjects who have previously been enrolled into this study and subsequently withdrawn.

Sponsors & Collaborators

• Lpath, Inc.: lead

Study Sites (3)

Premiere Oncology

Scottsdale, Arizona, 85260, United States

Location

Pacific Oncology

San Diego, California, United States

Location

Premiere Oncology

Santa Monica, California, 90404, United States

Location

Related Publications (1)

• Visentin B, Vekich JA, Sibbald BJ, Cavalli AL, Moreno KM, Matteo RG, Garland WA, Lu Y, Yu S, Hall HS, Kundra V, Mills GB, Sabbadini RA. Validation of an anti-sphingosine-1-phosphate antibody as a potential therapeutic in reducing growth, invasion, and angiogenesis in multiple tumor lineages. Cancer Cell. 2006 Mar;9(3):225-38. doi: 10.1016/j.ccr.2006.02.023.

  PMID: 16530706 BACKGROUND

MeSH Terms

Conditions

Neoplasms

Interventions

sonepcizumab

Study Officials

• William Garland, PhD

  Lpath, Inc.

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 15, 2008
• First Posted: April 18, 2008
• Study Start: April 1, 2008
• Primary Completion: December 1, 2011
• Study Completion: December 1, 2011
• Last Updated: January 31, 2012

Record last verified: 2012-01

Locations

US (3)